Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan.
Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan;
In Vivo. 2022 Sep-Oct;36(5):2379-2383. doi: 10.21873/invivo.12970.
BACKGROUND/AIM: This study aimed to determine whether a high neutrophil-lymphocyte ratio (NLR) was associated with the occurrence of febrile neutropenia (FN).
Japanese patients with esophageal cancer who had been treated with first-line 5-fluorouracil and cisplatin therapy at Fujita Health University from April 2016 to March 2021 were enrolled in this retrospective cohort study. The primary outcome was the identification of independent risk factors for FN.
One hundred and fourteen patients were enrolled. Advanced cancer (hazard ratios (HR)=6.731) and an NLR ≥3 (HR=4.849) were identified as risk factors for FN. Furthermore, FN occurred earlier in patients with high NLR than in patients with low NLR.
Advanced cancer and a high NLR might be predictors of the occurrence of severe neutropenia and FN in patients treated with 5-fluorouracil and cisplatin therapy.
背景/目的：本研究旨在确定高中性粒细胞与淋巴细胞比值（NLR）是否与发热性中性粒细胞减少症（FN）的发生有关。
本回顾性队列研究纳入了 2016 年 4 月至 2021 年 3 月在藤田保健卫生大学接受一线 5-氟尿嘧啶和顺铂治疗的食管癌日本患者。主要结局是确定 FN 的独立危险因素。
共纳入 114 例患者。晚期癌症（风险比（HR）=6.731）和 NLR≥3（HR=4.849）是 FN 的危险因素。此外，高 NLR 患者的 FN 发生时间早于低 NLR 患者。
在接受 5-氟尿嘧啶和顺铂治疗的患者中，晚期癌症和高 NLR 可能是严重中性粒细胞减少和 FN 发生的预测因素。
